Stephen Lucero, MD
Urology · Santa Fe, NMNPI 1154414027
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $926 of the $1,541 with a category attached, or 60.1%. 13 manufacturers reported payments, led by Procept Biorobotics Corporation at 57.9% of the total. 2025 is the largest year on record at $1,062, 7.7 times the $137 reported in 2019.
Across 31 payments — averaging $49.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$892
- Johnson & Johnson$150
- Pfizer$136
- Bolton Medical Inc$99
- Boehringer Ingelheim$61
- Tactile Systems Technology Inc$60
- plus $143 from 7 others
What the payments were for
- Travel & lodging$55436%
- Food & beverage$92660%
- Education$614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 12 | $892 |
| Johnson & Johnson | 1 | $150 |
| Pfizer | 5 | $136 |
| Bolton Medical Inc | 1 | $99 |
| Boehringer Ingelheim | 1 | $61 |
| Tactile Systems Technology Inc | 3 | $60 |
| Tolmar Pharmaceuticals, Inc. | 2 | $35 |
| Merck | 1 | $26 |
| Biotissue Holdings Inc. | 1 | $20 |
| Boston Scientific | 1 | $17 |
| Convatec Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$637
- RYBREVANT$150
- CARVYKTI$150
How this compares
$1,541 in reported general payments places this provider in the 55th percentile of 46 urology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 17 | $367,341 |
| MyrbetriqMirabegron | 42 | $30,582 |
| Tamsulosin Hcl | 939 | $14,609 |
| Finasteride | 613 | $7,695 |
| Testosterone | 26 | $4,516 |
| Oxybutynin Chloride ErOxybutynin Chloride | 207 | $2,881 |
| Dutasteride | 21 | $2,349 |
| Ciprofloxacin Hcl | 109 | $1,427 |
| Solifenacin Succinate | 37 | $1,005 |
| NitrofurantoinNitrofurantoin Macrocrystal | 33 | $940 |
| Doxazosin Mesylate | 90 | $919 |
| Tadalafil | 12 | $773 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 28 | $748 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 37 | $703 |
| Bicalutamide | 27 | $701 |
Paid to pharmacies, not to this prescriber.
Other urology in Santa Fe
- Eric AndersonSanta Fe$2K
- Margaret leSanta Fe$2K
- Benjamin MontgomeryLovington$166K
- Wayne KuangAlbuquerque$128K
- Jordan ForemanAlbuquerque$60K
- Emma BendanaLas Cruces$18K
- Andrew GrollmanAlbuquerque$16K
- Aaron GeswaldoAlbuquerque$11K
- Jonathan NelsonAlbuquerque$6K
- Robert KolosseusLas Cruces$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.